A study published in Nature Microbiology now shows for the first time that Candida auris uses a CO₂-based metabolic strategy to survive in the nutrient-poor conditions of the skin and to better tolerate antifungal therapies – especially amphotericin B (AMB).24. Dezember 2025
Health Lilly’s New Oral GLP-1 Orforglipron Led to 12% Weight Loss in TrialsHealthradar14. August 2025 Share on PinterestGLP-1 drugmaker Eli Lilly’s new weight loss pill orforglipron showed meaningful weight loss results in a recent clinical…
